Update on the Management of Cholangiocarcinoma

J.R.A. Skipworth, M.G. Keane, S.P. Pereira

Department of Surgery and Interventional Science, University College London, and Institute for Liver and Digestive Health, University College London Medical School, London, UK

Introduction

Cholangiocarcinoma (CC) is a rare tumour of cholangiocytes (epithelia of the biliary tract) [1] with an incidence in the UK of approximately 1–2 per 100,000 population [2, 3]. However, the incidence (particularly of intrahepatic tumours) continues to rise annually both within the UK and worldwide [3–6], and in the mid-1990s CC overtook hepatocellular carcinoma as the commonest cause of liver cancer death in the UK [7]. Established risk factors for CC include male sex, increasing age, smoking and diabetes [4].

Up to 70% of CC arise from the hilar region (also known as Klatskin tumours) and involve the main extrahepatic bile duct and right or left hepatic ducts [1]. Almost all other tumours are extrahepatic, involving the distal common bile duct [1]. Hilar and extrahepatic tumours typically cause progressive occlusion of the external biliary tree and present with painless obstructive jaundice, with or without cholangitis. Only rarely do tumours arise from smaller intrahepatic bile ducts, often forming a solitary, compressive mass that may result in non-specific symptoms such as right upper quadrant discomfort, anorexia and nausea.

Key Words

Biliary tract carcinoma · Cholangiocarcinoma · Surgery · Neoadjuvant therapy · Adjuvant therapy
The late presentation of CC patients is thought to be due in part to a lack of consistently effective biomarkers and diagnostic tools for the detection of early disease. CA (carbohydrate antigen) 19-9 remains the most widely used biomarker for the diagnosis of CC; however, it is undetectable in approximately 7% of the population who are deficient in the fucosyltransferase enzyme required for its production [8, 9]. CA19-9 is also non-specific and can be elevated in pancreatic adenocarcinoma, primary biliary cirrhosis, cholestasis, cholangitis and in smokers [10]. However, a combination of CA19-9, magnetic resonance cholangiopancreatography (MRCP) and endoscopic or percutaneous tissue sampling represents the standard technique for diagnosing CC. Recently, several novel endoscopic techniques such as per-oral cholangioscopy, confocal endomicroscopy and fluorescence in situ hybridisation (FISH) of biliary brushings have been shown to enhance the accuracy of standard endoscopic retrograde cholangiopancreatography (ERCP) in diagnosing CC [11–13].

Prognosis in unresectable CC is poor (6–12 months) and therapeutic options have historically been limited. However, recent combinations of chemotherapy agents, biological therapies and novel local therapies have been shown to be associated with significant improvements in overall survival. Due to the rarity of the disease, many of these treatments have so far only been evaluated in small studies and validation through larger prospective studies will be required to ultimately define their role in future algorithms for the management of CC (fig. 1).

Surgical Management of Resectable Cholangiocarcinoma

Preoperative Assessment and Optimisation

Only a minority of patients with CC (15–35%) are suitable for surgical treatment. Assessment of suitability relies on accurate cross-sectional imaging and endoscopic modalities to characterise the tumour’s anatomical site as
well as the extent of local and metastatic spread [4, 14–17]. However, gradual infiltration along the biliary tract, associated with the common presence of low volume but multifocal disease, can result in CC being understaged by cross-sectional imaging. Although ultrasound and high-resolution computed tomography (CT) are useful for the initial assessment of the liver and biliary system and to exclude metastatic spread, magnetic resonance imaging (MRI) with contrast angiography provides the most accurate assessment of biliary anatomy, local invasion and the extent of involvement of crucial nearby ductal and vascular structures, with a reported accuracy in localising the site and cause of biliary obstruction of 100 and 95%, respectively [18].

The current use of positron-emission computed tomography (PET-CT) in patients with suspected CC remains limited due to lack of access and the common presence of cholangitis, which can make interpretation difficult; however, its use may become more important in the future [19, 20]. Cytological or histological confirmation is usually obtained following cross-sectional imaging, commonly by ERCP. Endoscopic techniques remain crucial as the majority of patients diagnosed have unresectable disease and provision of adequate biliary drainage is necessary to prevent sepsis and enable palliative chemotherapy. However, when employed for diagnostic purposes, standard ERCP and brush cytology has a sensitivity for malignancy of only 9–57% [21–24], although this may be improved by techniques such as FISH and digital image analysis, which enable the analysis of DNA abnormalities in brush cytology [23]. Further techniques, such as methylene blue, narrow-band imaging, autofluorescence, confocal laser endomicroscopy and elastic scattering spectroscopy are not routinely used but may allow an augmented view of the visualised mucosa during ERCP [25–28].

Alternative endoscopic methods include endoscopic ultrasonography with fine-needle aspiration (EUS–FNA), which provides a method for visualising and sampling the extrahepatic biliary tree, hilar masses, and perihilar ductal and vascular structures, with a sensitivity and specificity of up to 89 and 100%, respectively [29], or single-operator cholangioscopy systems (Spyglass; Boston Scientific Corp., Natick, Mass., USA). In cases of uncertainty regarding resectability, staging laparoscopy can provide additional information about tumour extension, liver atrophy or metastatic disease and approximately a third of such patients will be found to have irresectable disease [17, 30, 31].

Preoperative biliary drainage in the presence of jaundice, via endoscopically-placed bile duct stents, leads to improvements in liver function and outcome following hepatic resection [32–35]. Percutaneous, transhepatic radiological techniques [e.g. percutaneous transhepatic cholangiography (PTC)] for drainage of unilateral bile ducts can also be used and may have a similar or lower complication and failure rate than endoscopic techniques [33–39].

Portal vein embolization or ligation should also be utilised preoperatively to promote hypertrophy of the liver remnant in situations where it is predicted to be less than 25% or there is unresolved preoperative jaundice, and is associated with a reported reduction in postoperative hepatic failure from 20 to 6% [40–43]. Such improvements in preoperative optimisation have led to a growing number of patients with CC being eligible for surgical resection [16].

Surgical Resection

Tumour resection with clear pathological margins offers the best long-term survival and recurrence rates in CC; an aggressive resectional strategy is therefore the mainstay of treatment [4, 15, 16]. Hepatic resection with concurrent excision and anastomosis of the portal vein and/or bile duct is considered standard treatment and has been associated with a reduction in associated morbidity and mortality [44, 45]. Specific complication, survival and recurrence rates following surgery are related to the precise nature of the surgery the patient undergoes, which in turn is dictated by the anatomical site and extent of the tumour. Patients with intrahepatic tumours will require segmental liver resection or hemihepatectomy; those with extrahepatic bile duct tumours will undergo hilar and bile duct resection, with partial hepatic resection if the bile duct bifurcation is also affected, and ampullary or distal bile duct tumours will be resected by Whipple's pancreaticoduodenectomy [7, 46].

Thirty-day mortality following a resection for CC ranges from 2 to 25% in various series with significant complications including bile leak, cholangitis, haemorrhage and intra-abdominal collections, occurring in up to approximately two thirds of patients [15, 17, 43, 47–51]. Mortality rates are increased in those with significant co-morbidities, hypoalbuminaemia and jaundice in the preoperative period [15, 17, 43, 47–51] but is now similar in those undergoing extended resection (with or without vascular resection) and those having extensive hepatic resection [49, 50, 52]. The commonest postoperative complication contributing to patient death remains hepatic failure, the risk of which increases with the amount of hepatic tissue resected [48, 50]. ALPPS
(Associating Liver Partition with Portal vein ligation for Staged hepatectomy) is a novel two-stage resection technique involving initial in-situ transection of liver parenchyma (along the intended line of hepatic resection or falciform ligament) and portal vein ligation, with subsequent staged (7–14 days later) completion hepatectomy [53]. When compared to portal vein embolization, this strategy results in rapid volume growth of the future liver remnant (FLR; up to 75% increase) with the most rapid growth occurring within the first 3 days of the procedure. This technique thereby enables resection of tumours that would have been previously considered to be unresectable because of the predicted small size of the FLR. ALPPS can also be utilised following initial portal vein embolization if there has been insufficient FLR volume increase [53, 54].

CC is associated with a median overall 5-year survival of 20–36 months; however, in those patients in whom complete pathological resection is possible [16, 17, 55–57], median survival increases to 65 months [4, 16, 48, 52]. Median survival rates also vary according to the site of the tumour (hilar tumours 18–30 months, perihilar tumours 12–24 months, extrahepatic 16–30 months) [6, 15, 58–61] and the presence of postoperative residual disease, which leads to a significant decrease in survival rates [62].

Factors that have been associated with prolonged postoperative survival include small, early stage or well-differentiated, unifocal tumours, without regional nodal disease or macroscopic portal vein invasion [4, 15–17, 49]. However, even following successful resection, recurrence is common, occurring in up to 63% overall within 2 years [4].

Liver Transplantation
Liver transplantation negates any requirements for negative resection margins following en-bloc resection of the liver, bile ducts and hilar lymphatics, but remains limited by the scarcity of donors.

Recent results have suggested that a combination of orthotopic transplantation and neoadjuvant chemoradiotherapy regimens offer excellent long-term (5-year) survival rates of up to 82% in patients previously considered unresectable [63–65]. Recurrence rates are also lower than in resected patients (13 vs. 27%) [63]. However, there are difficulties in direct comparison with resected patients in that transplanted patients tend to be younger, have fewer co-morbidities, have node-negative disease and almost always undergoing neoadjuvant therapy [66].

Treatment of Locally Advanced and Metastatic Cholangiocarcinoma

The prognosis for patients with locally advanced or recurrent CC is poor. The goals of palliative therapy in such patients are to relieve symptoms and improve overall quality of life. There is no role for tumour debulking in advanced CC.

Endoscopic Biliary Decompression in Malignant Obstruction
Biliary drainage is essential in CC to prevent septic complications from cholangitis and enable patients to be eligible for palliative chemotherapy. Effective endoscopic biliary stenting to relieve obstruction has been associated with fewer short-term complications and longer survival (19 vs. 16.5 months), as well as being more cost-effective than surgical decompression [67]. In most centres, endoscopic or percutaneous management of biliary obstruction is therefore the standard initial approach in treating patients with malignant biliary obstruction.

Distal Common Bile Duct Obstruction
A meta-analysis of seven studies (1992–2006) compared plastic stents to self-expanding metal stents (SEMS) for malignant distal biliary obstruction and found that the relative risk of recurrent biliary obstruction was significantly lower (RR = 0.52) in the metal stent group [68]. Since uncovered SEMS are permanent, many patients are initially managed with a plastic stent while confirmation of malignancy is obtained. However, the introduction of removable covered metal stents has changed this practice. Four randomised controlled trials have compared uncovered and covered SEMS in the management of distal biliary obstruction: in the earlier three studies, no significant differences in stent patency time, survival or complication rates were observed but covered stents did migrate more frequently [69–71]. However, in the most recent randomised trial incorporating patients with distal biliary obstruction secondary to pancreatic carcinoma, survival without stent dysfunction was significantly longer in the covered SEMS group (187 vs. 132 days, $p = 0.043$) and no difference in stent migration was observed [72].

Proximal Biliary Obstruction
Hilar CC can lead to disconnection of the right and left biliary systems and several studies have attempted to define optimal stenting practice in this situation. A prospective, observational study reported that plastic stent

Update on Cholangiocarcinoma

Dig Dis 2014;32:570–578
DOI 10.1159/000360507

573
placement was associated with a poorer 30-day outcome (cholangitis, stent occlusion, migration, perforation, unplanned ERCP or PTC) compared with metal stents (OR 6.32; 95% confidence interval 1.23, 32.56) [73].

A single biliary stent will achieve decompression in most patients (80%) with hilar CC [74, 75]; however, in a retrospective study comparing the efficacy of unilateral and bilateral stent placement, functional success was significantly higher (97.9 vs. 84.8%, p < 0.001) and complications fewer (56.4 vs. 24.4%, p < 0.001) in the bilateral SEMS group. Placement of SEMS rather than plastic stents was also associated with longer stent patency times (24 vs. 29 weeks, p < 0.0001) [76]. A further randomised study observed that rates of successful drainage were significantly higher following SEMS placement (70.4 vs. 46.3%, p = 0.1) and overall survival was longer (126 vs. 49 days, p = 0.002) [77].

**Novel Endoscopic and Percutaneous Local and Ablative Therapies**

**Photodynamic Therapy**

Photodynamic therapy (PDT) is a novel ablative technique that results in localised tissue necrosis following the application of either visible or near-infrared light (usually from a low-power, red laser) after prior administration of a photosensitising agent. Randomised studies comparing PDT with biliary stenting with stenting alone have provided conflicting results. Initial studies reported prolonged stent patency and improved survival after PDT [78, 79]; however, a subsequent UK phase III study closed early as overall survival was longer in those treated with stenting alone [80].

**Radiofrequency Ablation**

Radiofrequency ablation (RFA) in combination with SEMS placement has been evaluated in a small study of 22 patients, which found that all stents were patent 30 days after the procedure [81]. Only rarely have centres described the use of RFA alone to achieve biliary drainage and randomised controlled trials are ongoing to evaluate this technique [82]. Current guidance from the National Institute for Health and Care Excellence in the UK recommends that the treatment is only carried out in specialist centres in the context of clinical trials [83].

**Transarterial Chemoembolization**

Transarterial delivery of embolic and cytotoxic agents leads to local tumour ischaemia and targeted chemotherapy, which, in unresectable hepatocellular carcinoma, has been associated with improved survival and resulted in its incorporation into many standard treatment algorithms [84]. Recently, it has been used in the treatment of advanced CC: a prospective study of 115 patients with unresectable CC treated with transarterial chemoembolization (TACE) found that more than half of the patients survived over 1 year (median survival 13 months) [85]. A recent retrospective study has also observed TACE to be an equivalent treatment to surgery for CC in those in whom an R0 resection (negative pathological margins) was not achieved [86].

**Chemotherapy**

A multicentre, randomised phase III study comparing cisplatin and gemcitabine to gemcitabine alone in the treatment of advanced biliary tract cancer (ABC-02) was associated with an improved median survival in the combination group (11.7 vs. 8.1) [87]. Improved progression-free survival and disease control rates were also demonstrated. Prior to the ABC-02 trial, patients with advanced CC received a range of chemotherapy regimens; however, a large retrospective review from the UK compared overall survival in patients receiving gemcitabine, fluoropyrimidine or platinum-based treatments and found that fluoropyrimidine may be as effective as gemcitabine in the treatment of advanced CC [88]. Initial prospective studies which combined gemcitabine- and fluoropyrimidine-based treatments observed prolonged survival (14 months) with relatively few complications [89].

**Neoadjuvant Chemoradiotherapy for CC**

The primary aim of neoadjuvant therapy is to downstage malignant disease, rendering tumours suitable for surgical resection or transplantation. In other solid organ malignancies both radio- and chemotherapy have been observed to be more effective in the neoadjuvant setting. In unresectable perihilar CC, a large case series included 287 patients from 12 large-volume transplant centres in the USA. Seventy-one patients did drop out prior to liver transplantation, but recurrence-free survival rates were 78 and 65% at 2 and 5 years, respectively [90]. A further case series of 45 patients with extrahepatic disease, 12 of whom were treated neoadjuvantly. Three had a complete pathological response and 11 were able to undergo R0 resection. In addition, despite having more advanced disease at presentation, those who received neoadjuvant chemoradiotherapy had a longer 5-year survival (53 vs. 23%, p = 0.16) [91]. Although these results are promising, neoadjuvant regimens are currently not part of the standard management of CC.
Adjuvant Chemotherapy for CC

Postoperative adjuvant therapy is widely recommended for all patients with intra- or extrahepatic CC who have microscopically positive resection margins, as well as for those with a complete resection but node-positive disease. However, even following R0 resection in CC, locoregional recurrence remains high. Currently there is no established treatment protocol for those patients undergoing attempted curative resection for CC but in whom negative histological margins are not achieved. Small studies of adjuvant therapy have demonstrated promising results; the outcome of the UK BILCAP randomised controlled trial, which is evaluating the role of adjuvant chemotherapy with capecitabine (an oral 5-fluorouracil analogue), following surgical resection, is awaited.

Radiotherapy

External beam radiotherapy and intraluminal brachytherapy have been evaluated in CC [92–94]. Most studies to date have compared patients with historical controls and results have been equivocal. McMasters et al. [95] described a case series of 9 patients with extrahepatic CC who were successfully downstaged with external beam radiotherapy: 100% had negative resection margins following surgery. However, in a longer-term study by González González et al. [96], which used combinations of pre- and postoperative external beam radiotherapy, no impact on 1-, 3- or 5-year survival was observed. More recently, Gwak et al. [97] observed a downward trend in 5-year survival following adjuvant radiotherapy (21 vs. 11.6%). Thus, large prospective studies are lacking and at present the evidence does not support the use of adjuvant radiotherapy in patients with negative resection margins [98].

Few studies have evaluated chemoradiotherapy in CC. Kim et al. [99] followed 72 extrahepatic CC patients that had undergone surgical resection (47 with negative margins and 25 with positive margins) and then went on to receive postoperative external beam radiotherapy (40 Gy) and concomitant boluses of 5-fluorouracil (500 mg/m²): the 5-year survival rates were 36% following R0 resection, 35% following R1 resection, and 0% following R2 resection. Nakeeb and Pitt [100] similarly reported improved survival with chemoradiotherapy. Although these studies are small, they appear to support the use of radical resection followed by chemoradiotherapy in CC.

Biological Therapies

To date, several pilot studies have investigated the role of molecularly targeted therapies in CC. For example, in vitro studies of the multikinase inhibitor sorafenib have shown that it inhibits proliferation of CC cell lines in culture in a dose-dependent manner [101] and causes significant tumour suppression in a rodent model [102]. However, limited phase II studies to date in CC have not demonstrated a clinical benefit [103]. The French BINGO trial randomised 101 patients to receive gemcitabine and oxaliplatin (GEMOX) with or without cetuximab [104]. Initial findings demonstrated 4-month progression-free survival rates of 50% in the GEMOX arm and 61% in the GEMOX with cetuximab arm.

Conclusion

Despite significant advances in the treatment of patients with CC, the only potential for long-term survival remains surgical resection or liver transplantation. Unfortunately, this remains only possible in a minority of patients and both neoadjuvant and adjuvant therapies currently provide only a limited survival improvement in selected patients with advanced disease. To achieve improved outcomes, better understanding of tumour biology, combined with the development of novel diagnostic and treatment strategies, is crucial.

Acknowledgements

The work was undertaken at UCLH/UCL, which received a proportion of funding from the Department of Health’s National Institute for Health Research (NIHR) Biomedical Research Centres funding scheme.

Disclosure Statement

The authors have no conflicts of interest to disclose.

References


Update on Cholangiocarcinoma

DOI: 10.1159/000360507


83 NICE: Using radiofrequency energy to treat malignant bile or pancreatic duct obstructions caused by cholangiocarcinoma or pancreatic adenocarcinoma. 2013.


